Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02532036
Other study ID # TB040
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date September 2015
Est. completion date October 4, 2018

Study information

Verified date November 2018
Source University of Oxford
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

TB040 is a clinical trial to investigate and compare the effects of a candidate Tuberculosis (TB) vaccine, MVA85A, administered by the aerosol inhaled route and the intramuscular route in healthy adult volunteers who are latently infected with Mycobacterium tuberculosis.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date October 4, 2018
Est. primary completion date October 4, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

Volunteers must meet all of the following criteria to enter the trial:

- Healthy adult aged 18-55 years

- Resident in or near Oxford, Birmingham or London for the duration of the trial period

- Screening IGRA positive

- Ineligible for chemoprophylaxis for latent M.tb infection, declined prophylaxis or considered low risk due to distant contact history

- Chest Computed Tomography (CT) normal; or abnormal with features consistent with primary M.tb infection but no features suggestive of active disease

- No relevant findings in medical history or on physical examination

- Allow the Investigators to discuss the individual's medical history with their General Practitioner

- Use effective contraception for the duration of the trial period (females only)

- Refrain from blood donation during the trial

- Give written informed consent

- Allow the Investigator to register volunteer details with a confidential database (The Over-volunteering Protection Service) to prevent concurrent entry into clinical trials

- Able and willing (in the Investigator's opinion) to comply with all the trial requirements

Exclusion Criteria:

Volunteers must meet none of the following criteria to enter the trial:

- Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the trial period

- Prior vaccination with candidate vaccine MVA85A, candidate vaccine FP85A,any other recombinant MVA vaccine or any other candidate TB vaccine

- Administration of immunoglobulins and/or any blood products within the three months preceding the planned trial vaccination date

- Clinically significant history of skin disorder, allergy, atopy, immunodeficiency (including HIV), cancer (except BCC or CIS), cardiovascular disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder, neurological illness, psychiatric disorder, drug or alcohol abuse

- Concurrent oral or systemic steroid medication or the concurrent use of other immunosuppressive agents

- History of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine, sedative drugs, or any local or general anaesthetic agents

- Pregnancy, lactation or intention to become pregnant during trial period

- Any respiratory disease, including asthma

- Current smoker

- Clinically significant abnormality on screening CT thorax

- Clinically significant abnormality of pulmonary function tests

- Any nasal, pharyngeal, or laryngeal finding which precludes bronchoscopy

- Current use of any medication taken through the nasal or inhaled route including cocaine or other recreational drugs

- Clinical, radiological, or laboratory evidence of current active TB disease

- Past treatment for TB disease

- Any clinically significant abnormality of screening blood or urine tests

- Positive HBsAg, HCV or HIV antibodies

- Any other significant disease, disorder, or finding, which, in the opinion of the Investigator, may either put the volunteer at risk, affect the volunteer's ability to participate in the trial or impair interpretation of the trial data

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Aerosol inhaled MVA85A

Intramuscular MVA85A

Intramuscular Saline placebo

Aerosol inhaled Saline placebo


Locations

Country Name City State
United Kingdom NIHR Wellcome Trust Clinical Research Facility, University of Birmingham Birmingham West Midlands
United Kingdom NIHR/Wellcome Trust King's Clinical Research Facility London
United Kingdom Royal Free Hospital NHS Foundation Trust London
United Kingdom Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Churchill Hospital Oxford Oxfordshire
United Kingdom John Warin Ward, Churchill Hospital Oxford Oxfordshire

Sponsors (2)

Lead Sponsor Collaborator
University of Oxford University of Birmingham

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse Events (AE) Actively and passively collected data on adverse events via diary card for 14 days after vaccination and at each visit over 6 months. Up to Day 168
Secondary Laboratory Markers of Immunity Evaluation of ex-vivo ELISpot and intracellular cytokine staining in blood and bronchoalveolar lavage (BAL) samples. Up to Day 168
See also
  Status Clinical Trial Phase
Recruiting NCT05738681 - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT05526885 - Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa N/A
Completed NCT04369326 - Community Initiated Preventive Therapy for TB N/A
Recruiting NCT04568967 - TB-CAPT EXULTANT - HIV N/A
Completed NCT02337270 - Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol Phase 1
Not yet recruiting NCT06253715 - Shortened Regimen for Drug-susceptible TB in Children Phase 3
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Withdrawn NCT03639038 - Tuberculosis Diagnosis by Flow Cytometry
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Recruiting NCT04975178 - Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa Phase 3
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03973970 - Assessing the Ability of the T-SPOT®.TB Test (IQ)
Recruiting NCT04230395 - Alcohol Reduction Among People With TB and HIV in India N/A
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Active, not recruiting NCT02906007 - Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV Phase 1/Phase 2
Not yet recruiting NCT05917210 - Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda N/A
Not yet recruiting NCT05845112 - Start Taking Action For TB Diagnosis
Not yet recruiting NCT06017843 - Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding N/A
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Completed NCT02781909 - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis Phase 2